603229.SH
奥翔药业
SSE · Healthcare · Biotechnology · CN
CNY 7.94
−1.98%Year over year
Reported trailing growth
- Revenue
- -0.8%
- EBITDA
- —
- EBIT
- -55.3%
- EPS
- -48.7%
- Free cash flow
- -9.2%
- Operating cash flow
- -21.3%
Forward estimates
Based on analyst estimates
- Revenue
- -56.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.2%
- EBITDA
- -9.8%
- EBIT
- -18.4%
- Net income
- -17.8%
- EPS
- -26.9%
- Free cash flow
- -5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026